Clinical combinations: ever increasingly, two study products are better than one

Forgive the poetic licence but it feels like almost every week a new agreement for a clinical combination therapy lands on our desks.

Drug combination therapy has been a popular approach to clinical research and treatment for decades now, with many notable successes showing improved treatment response for patients or the reduction of adverse events. However, from an eye-ball test at least[1], clinical combinations appear to be increasingly commonplace – particularly in the field of oncology – and we seem to be advising on these agreements far more frequently in recent times.

Therefore to aid readers about to start, or perhaps already in the midst of, negotiating a clinical combination therapy agreement, we thought it would be helpful to identify, and offer some guidance on, three of the key topics we regularly encounter when advising clients on these arrangements.

Continue reading

=======================

[1] Although note there does seem to appear to be academic research supporting this view, see for example the following article:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441974/#:~:text=Combination%20therapies%20are%20increasingly%20prevalent,rational%20design%20and%20industry%20trends